| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| keynote 522 trial regimen | 0.55 | 0.3 | 4562 | 56 | 25 |
| keynote | 0.66 | 0.6 | 9679 | 27 | 7 |
| 522 | 0.58 | 0.6 | 5271 | 25 | 3 |
| trial | 0.71 | 0.7 | 607 | 20 | 5 |
| regimen | 0.35 | 0.1 | 330 | 16 | 7 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| keynote 522 trial protocol | 0.47 | 0.9 | 1593 | 32 |
| what is keynote 522 regimen | 1.17 | 0.8 | 61 | 9 |
| keynote 522 regimen schedule | 0.43 | 0.9 | 203 | 25 |
| keynote 522 clinical trial | 1.8 | 0.1 | 5147 | 13 |
| keynote 522 trial design | 0.27 | 0.8 | 832 | 37 |
| keynote 522 chemo regimen | 0.74 | 1 | 9616 | 48 |
| keynote 522 treatment plan | 1.66 | 0.8 | 1780 | 25 |
| keynote 522 breast cancer trial | 1.25 | 0.5 | 3845 | 16 |
| keynote 522 updated results | 0.84 | 0.4 | 4709 | 70 |
| keynote 522 fda approval | 0.15 | 1 | 791 | 13 |
| keynote 522 protocol nejm | 1.4 | 0.2 | 8613 | 29 |
| keynote-522 | 1.3 | 0.3 | 1677 | 58 |
| keynote-522 fda | 1.8 | 0.7 | 8706 | 98 |
| keynote 522 overall survival | 0.26 | 0.1 | 4600 | 48 |
| keynote 522 breast cancer | 0.96 | 1 | 8973 | 17 |
| adjuvant keytruda keynote 522 | 1.38 | 0.5 | 5464 | 10 |
| keynote-177 trial | 0.37 | 0.1 | 2693 | 7 |
| keynote 522 triple negative breast cancer | 1.08 | 0.3 | 8864 | 62 |
| keynote 522 adjuvant pembrolizumab | 1.79 | 0.9 | 7363 | 63 |
| keynote 522 nejm 2022 | 0.84 | 0.6 | 2433 | 47 |
| keynote-028 trial | 0.91 | 0.1 | 4370 | 15 |
| keynote 522 trial regimen | 1.95 | 0.4 | 612 | 83 |
